Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN3470-3471-3479 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 1 or placebo |
| Cohort 2 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 2 or placebo |
| Cohort 3 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 3 or placebo |
| Cohort 4 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 4 or placebo |
| Name | Type | Description |
|---|---|---|
| REGN3470-3471-3479 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Healthy man or woman between the ages of 18 and 60 2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide signed informed consent 5. Able to understand and complete study-related que...
REGN3470-3471-3479 is an investigational drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, and pharmacokinetics in healthy adult volunteers. The drug is not approved for any indication and remains in clinical testing.
REGN3470-3471-3479 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company. Regeneron is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers. The company's stock is traded under the ticker symbol REGN.
REGN3470-3471-3479 is in Phase 1 clinical development. A Phase 1 study has been completed, which involved 24 healthy adult volunteers. The drug is investigational and has not been approved by regulatory authorities. It is still in the early stages of clinical testing.
REGN3470-3471-3479 has one completed clinical trial, identified as NCT02777151. This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy adult volunteers. The trial was conducted in the United States and enrolled 24 participants.
REGN3470-3471-3479 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy volunteers. The drug is still in clinical development and has not been approved for any medical use by the FDA or other regulatory agencies.